Focus Partners Wealth
HUMA icon

Focus Partners Wealth’s Humacyte HUMA Stock Holding History

Focus Partners Wealth’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.6K Buy
23,854
+10,434
+78% +$9.67K ﹤0.01% 2736
2026
Q1 		$8.14K Buy
+13,420
New +$14K ﹤0.01% 2636
2025
Q3 		– Sell
-10,282
Closed -$21.5K – 2255
2025
Q2 		$21.5K Buy
+10,282
New +$19.8K ﹤0.01% 2004

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Focus Partners Wealth's HUMA Position: Q2 2026 in Review

Focus Partners Wealth increased its Humacyte (HUMA) stake by 78% in Q2 2026, buying an estimated $9.67K and bringing the position to 23,854 shares worth $18.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2736.

Focus Partners Wealth first reported a position in HUMA in Q2 2025 and has held it in 3 quarters since. The position peaked at $21.5K in Q2 2025. 164 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Focus Partners Wealth held 23,854 shares of Humacyte worth $18.6K as of Q2 2026.
  • Focus Partners Wealth bought 10,434 Humacyte shares in Q2 2026, an estimated $9.67K.
  • Humacyte made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2736 holding.
  • Focus Partners Wealth first reported a position in Humacyte in Q2 2025 and has held it in 3 quarters since.
  • Focus Partners Wealth's Humacyte position peaked at $21.5K in Q2 2025.
  • 164 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.